GENinCode plc (AIM: GENI) has conditionally raised £3.9m in gross proceeds through the issue of 388,145,000 new ordinary shares at 1p each, representing a 47.4pc discount to the closing middle
GENinCode Plc (AIM: GENI) CARDIO inCode-Score® distribution with Sohin Genetics, Mexico
GENinCode Plc has entered into a commercial agreement with Sohin Genetics in Mexico to distribute its CARDIO inCode-Score® Polygenic Risk Score test, which is designed to help predict and prevent
GENinCode Plc (AIM: GENI) up 33% on Thermo Fisher commercialisation deal
GENinCode Plc (AIM: GENI) shares climbed 33% after the company announced a major collaboration with Thermo Fisher Scientific to commercialise its CARDIO inCode-Score® Polygenic Risk Score test for predicting and
GENinCode up 32% on NY approval for genetic heart risk test
GENinCode PLC (AIM: GENI) jumped 32% to 2.84p in early trading after securing approval from the New York State Department of Health (NYSDOH) for its CARDIO inCode-Score test, which assesses
GENinCode PLC (AIM: GENI) Result of Retail Offer
GENinCode plc (AIM: GENI.L), a genetics company focused on the prevention of cardiovascular disease (“CVD”) and the early detection of ovarian cancer, announced on 14 February 2025 the launch of a fundraising comprising a
GENinCode PLC (AIM:GENI) CARDIO inCode Lab Fee Update & Catalonia Launch
CARDIO inCode® inclusion in the US CMS 2025 Clinical Lab Fee Schedule and launch in the Spanish region of Catalonia
GENinCode PLC (AIM:GENI) Partnership with Genesupport SA for the ROCA® Test
GENinCode partners with Genesupport SA for the ROCA® Test in Switzerland Ovarian cancer surveillance using the ROCA Test to be made available to individuals across Switzerland
Angle PLC (AIM:AGL OTCQX:ANPCY) Study of ovarian cancer CTCs using Parsortix
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has reported encouraging results from a study using its Parsortix system to predict progression-free survival among ovarian cancer